| » View all news titles |
» View titles this week |
» View titles this month |
06/18/2018
Neuroblastoma is the most common extracranial solid tumor cancer in children, and patients with high-risk disease are challenging to treat. In a promising development, researchers at Baylor College of Medicine announced a Phase 1, first-in-human clinical trial of a new form of immunotherapy to treat neuroblastoma using genetically engineered natural killer T cells (NKTs).
